Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA completes review of supplemental BLA for Rituxan

Oct. 2, 2000

O-Vax ovarian cancer vaccine awarded orphan drug status in U.S.

Sep. 29, 2000

Corixa to file Melacine BLA for stage II melanoma

Sep. 29, 2000

Immunomedics commences phase III clinical trial with LymphoCide

Sep. 28, 2000

Vical reports interim data from phase II trial of Leuvectin

Sep. 26, 2000

ImmunoGen/SmithKline Beecham open second trial of cancer treatment

Sep. 26, 2000

Inhibition of NK cells by cancer cells from patients with CML prevented by Maxamine

Sep. 26, 2000

Biomira reports update of drug development programs

Sep. 25, 2000

Seattle Genetics initiates phase I trial of SGN-10 combination therapy

Sep. 21, 2000

Maxamine scheduled for December advisory panel review

Sep. 20, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...